In today’s recent session, 7.1 million shares of the ITeos Therapeutics Inc (NASDAQ:ITOS) have been traded, and its beta is 1.43. Most recently the company’s share price was $10.30, and it changed around $1.77 or 20.71% from the last close, which brings the market valuation of the company to $394.08M. ITOS at last check was trading at a discount to its 52-week high of $18.13, offering almost -76.02% off that amount. The share price’s 52-week low was $4.80, which indicates that the recent value has risen by an impressive 53.4% since then. We note from ITeos Therapeutics Inc’s average daily trading volume that its 10-day average is 3.06 million shares, with the 3-month average coming to 888.85K.
ITeos Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 3 recommended ITOS as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. ITeos Therapeutics Inc is expected to report earnings per share of -0.78 for the current quarter.
ITeos Therapeutics Inc (NASDAQ:ITOS) trade information
Instantly ITOS has been showing a green trend so far today with a performance of 20.71% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 11.35 on recent trading dayincreased the stock’s daily price by 9.25%. The company’s shares are currently up 34.07% year-to-date, but still up 23.31% over the last five days. On the other hand, ITeos Therapeutics Inc (NASDAQ:ITOS) is 45.63% up in the 30-day period. We can see from the shorts that 2.53 million shares have been sold at a short interest cover period of 4.93 day(s).
The consensus price target as assigned by Wall Street analysts is $12, which translates to bulls needing to increase their stock price by 14.17% from its current value. Analyst projections state that ITOS is forecast to be at a low of $9 and a high of $13.
ITeos Therapeutics Inc (ITOS) estimates and forecasts
The year-over-year growth rate is expected to be -100.00%, down from the previous year.
Analysts predict that the company’s current quarter sales will drop, forecast at -100.00%. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -34.39%. ITeos Therapeutics Inc earnings are expected to increase by 12.53% in 2025, but the outlook is positive 3.89% per year for the next five years.
ITOS Dividends
ITeos Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Apr-27.
ITeos Therapeutics Inc (NASDAQ:ITOS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.14% of ITeos Therapeutics Inc shares, and 111.04% of them are in the hands of institutional investors. The stock currently has a share float of 112.32%. ITeos Therapeutics Inc stock is held by 187.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 9.3983% of the shares, which is about 3.73 million shares worth $55.37 million.
RA CAPITAL MANAGEMENT, L.P., with 8.8598% or 3.52 million shares worth $52.2 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 855.64 shares worth $8.74 million, making up 2.24% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 725.88 shares worth around $7.41 million, which represents about 1.90% of the total shares outstanding.
